Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Spero Therapeutics closes $30mm Series B round

Executive Summary

Spero Therapeutics LLC (developing therapies to treat bacterial infections) raised $30mm in its Series B preferred equity financing to returning shareholders Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group, and Partners Innovation Fund. Proceeds will help further develop its potentiator platform, which is designed to disrupt the cell membrane of Gram-negative bacteria, allowing access for Gram-positive antibiotics. The additional money will also help advance its dihydrofolate reductase (DHFR) program, which is aimed at expanding the antibacterial spectrum of a novel antifolate in an effort to treat trimethoprim-resistant isolates, including key Gram-negative pathogens.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies